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Abstract
The following conclusions were drawn from the ferrokinetic studies using 59Fe in mice,
whose hematological disorders were induced by various treatments. 1. The ferrokinetics in
the normal mice were studied. 2. Chloramphenicol (CP) administration in mice first induced
ferrokinetics disturbances and then suppressed erythropoiesis. 3. Splenectomy induced hyper-
erythropoiesis in the bone marrow, and CP administration after splenectomy suppressed this hyper-
erythropoiesis. 4. Human gamma-globulin (H.G.G.) caused hypersplenism and a marked sup-
pression of erythropoiesis in the bone marrow, and Chlorabulin administration suppresed erythro-
poiesis. Finally, the author has summarized the relationship of the RES function and hematopoiesis
in mice as follows. 1. The spleen and liver reacted in the same manner with respect to the
RES function to sequestrate 51Cr-labelled heat-damaged erythrocytes when hematological fail-
ures were induced. 2. The spleen and bone marrow reacted reversely with regard to the RES
function. 3. When the RES function, especially that of the spleen was accentuated, the suppres-
sion of hematopoiesis was observed. 4. Chloramphenicol administration was followed by the
suppressed hematopoiesis and the accentuated RES function. 5. Splenectomy accentuated the
RES function in the bone marrow and liver, and also increased hematopoiesis in the bone mar-
row. 6. Human γ-globulin hypersensitization induced hyperfunction of the RES, especially of the
spleen and suppression of the hematopoiesis.
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It is assumed that there is a close relationship between the spleen and
the other hematopoietic organs. Many attempts have been made to
demonstrate the inhibitory effects of splenic extracts on hematopoiesis,
with equivocal results (1, 2). The existence of a humoral factor is sugges.
ted by observations of the effects of splenectomy and reimplantation of
splenic tissue (3,4). This possibility has intrigued investigators for many
years without conclusive evidence. The author already described the
relationship between RES function and hematopoietic organs in the
preceding paper (5). This paper is concerned with the ferrokinetics in
mice whose hematological disorders were induced by various methods.
MATERIALS AND METHODS
1. Mice: ICR female mice weighing 20 to 24 g were used in this experiment.
2. Peripheral blood pictures: Erythrocyte count/cmm and leucocyte count/cmm
were determined with blood from the tail vein of an individual mouse. Reticulo-
cyte counts were determined by the Pappenheim method.
3. Ferrokinetics: Plasma iron levels were measured by the Bathophenanthro-
line method with pooled plasma of several mice. Each mouse received 1.0 pc of
59Fe-ferrous citrate in 0.25 ml of physiologic saline from the tail vein. Twenty-
five pI of blood was obtained from the retroorbital venous plexus after 59Fe injec-
tion. The radioactivity in the capillary tube was then determined in a well-type
scintillation counter. The cpm in each specimen was plotted against time on
semilogarithmic paper, and plasma iron disappearance time (P. 1. D. T.) was
determined. The 5lFe disappearance curve was extrapolated on the Y-axis at
zero time, and the total cpm at zero time (cpm. ) in 25 pI of the whole blood was
calculated. The radioactivity of 25 pI of the whole blood obtained at 24 and 48
hours after injection of 53Fe was divided by cpmo so that the percentage of 59Fe
reappearance was determined. All the mice in this experiment were sacrificed
by decapitation at 1, 6, 24 and 48 hours after 59Fe injection. The liver, spleen,
femur, tibia and fibula were excised and weighed. The radioactivity of the liver
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and spleen was determined in a well-type scintillation counter. The percentage
of 59Fe uptake was calculated by dividing the cpm of either the liver or spleen by
the cpm of the 53Fe standard prepared at the time of radioiron injection. The
percent uptake of the bone marrow was assumed to be 13 times the total cpm of
femur, tibia and fibula.
4. Procedures to produce the hematological disorders: The hematological disorders
were induced with the same treatment as described in the preceding paper (5), (1)
CP(chloramphenicol) 3-day group, (2) CP 30-day group, (3) Spx. (splenectomy)
IO-day group, (4) Spx. 20-day group, (5) Spx. lO-day plus CP group, (6) Spx.
20-day plus CP group, (7) H. G. G. (human gamma globulin) group, (8) H. G. G.
& F. C. Adj. (Freund's complete adjuvant) group and (9) Chlorabulin group.
The study of ferrokinetics was started at 12 hours after the last administration of
CP, and four days after H. G. G. or Chlorabulin injection.
RESULTS
1. Normal mice: The normal value was determined in 20 normal mice;
Table
CP 30-day
2 roup
CP 3-day
g-roupNormal
- -
Erythrocyte (X lQ4/cmm) 1081 ±85t 1053±119 757±72*
Reticulocyte (%0) 28±15 16±1l 54±23
---_._-_._._.... -
Plasma Fe (,>,/dl) 242 298 350
P.I.D.T. (min.) 70±1O lOO±30** lOO±20*
59Fe Reappearance
I
24 h 83±13 33±13* 67±6
rate (%) 48 h 97±12 55±20* 82±3
I h 8.2±0.9 6.3±2.6 6.3±0.4
6 h 12.3±1.0 15.4±J.7 8.4±0.5*
~ Liver 13.5±1.2 17.3±2.0 9.3±0.2*24 h
~ 48 h 13.0±1.6 22.7±4.4 9.4±0.8*
,.>0:
l'll
:
0.. 1 h 8.5±2.3 2.3±1.8* 5.1 ±2.4
::J 6 h 1J. 7±2.6 2.7±1.9* 12.9±3.0
I:: Spleenl'll 24 h 5.9±0.8 2.1 ±0.5* 3.5±1.3**~
I
...
0 48 h J.4±0.1 O.8±0.2* 1.9±0.5
C 1-----1_-
'"
22.1 ±2.6 23.4±9.1 20.8±2.6u I h
...
~ Bone 6 h 31.2±3.9 33.8± 10.4 24.7±5.2**~
Marrow 24 h 18.2±2.6 19.5±3.9 16.9±2.6
I
48 h 9.1±J.3 I 14.3±3.9 7.8±J.3
t : Mean value±standard deviation.
* . P value showed significant difference less than 1 percent error (p < 0.01),
** . less than 5 percent (p <0.05) comparing normal group.
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Plasma iron levels: 242r /dl, erythrocyte counts: 1081 ± 85 X 104/cmm
(M±SD), reticulocyte counts: 28 ± 15 %0, P. 1. D. T.: 70± 10 min, 69Fe
reappearance rate: 83 ± 13 % after 24 hours, and 97 ± 12 % after 48
hours. The uptake of 69Fe in the spleen, liver and bone marrow is also
presented in Table 1. The maximum uptake of 69Fe into the spleen and
bone marrow occurred at 6 hours after 69Feinjection. The uptake of 69Fe
in the liver increased until 6 hours after injection and then remained
relatively constant during 48 hours. The radioactivity of the spleen
dropped in parallel with that of bone marrow after 24 and 48 hours.
2. CP 3-day group: As presented in Table 1, this group showed
elevated plasma iron levels, prolonged P. I. D. T. (p < 0.01), decreased
reticulocytes, and decreased 66Fe reappearance rate (p<O. 01). The uptake
of the bone marrow was normal but that of the spleen was significantly
low (p<O.Ol). The uptake of the liver was significantly high (p<O.Ol)
and increased with time during the observation. These facts indicated
that CP administration suppressed the erythropoietic function in the spleen
but not in the bone marrow.
3. CP·30 day group: This group showed higher plasma iron level,
prolonged P. I. D. T., and decreased erythrocytes (p<O. 01). 69Fe reappear-
Table 2
Spx 1O·~ay group Spx 20-day group
Erythrocytes (X 104jcmm) 784±103t* 866±75**
Reticulocyte (?6o) 30±6 26±5
Plasma Fe (I' j dl) 258 214
P. J.D. T. (min.) 75±15 70±10
59Fe Reappearance
I
24 h 70±13 49±1O*
rate (%) 48 h 80±9 79±1O
--------------
~ I h 7.6±\.4 9.2±0.4
~ 6 h 1\.8:.t\.0 7.3±0.9
-'" LiverCIS 24 h 12.9±2.3 11.2±\.9Q.
~ 48 h 1O.2± 1.3 1O.6±0.4
c
I
_._-_.
CIS
I
01) I h 29.6::L5.2 23.4±3.0...
0 Bone 6 h 36.4±0.2 35.1 ±7.8
=~ Marrow
I
24 h 16.9±0.2
I
23.4±\.3u
...
~ 48 h 6.5±1.3 10 .4::1:l . 3~ I
. - ---- '- -----
I
. --_ .. __._--- ----~_.~ ------ --- ----
t : Mean value±standard deviation.
* . P value S:lONd significant difference less than I percent error (p <0.01),
** . less than 5 percent (p <0.05) comparing normal group.
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ance rate was low after both 24 and 48 hours. The uptake of the marrow
and the liver was low, but that of the spleen was normal (Table 1). These
facts indicated that long-term administration of CP suppressed the erythro-
poietic function in the bone marrow but not in the spleen.
4. Spx. lO-day group: Erythrocyte counts decreased but the uptake
of the bone marrow was higher than that of the normal group (Table 2).
5. Spx. 20-day group: Erythrocyte counts returned to a normal range
and 59Fe reappearance rate was slightly low but the uptake of the bone
marrow was within the normal range (Table 2).
6. Spx. lO-day plus CP group: This group showed decreased erythrocyte
counts and high plasma iron levels. 59Fe reappearance rate was low and
the uptake of the bone marrow was decreased (Table 3).
7. Spx. 20-day plus CP group: Erythrocyte counts and 59Fe reappear-
ance rate were decreased and plasma iron levels were elevated in this
group as observed in Spx. lO-day plus CP group. But the uptake of the
bone marrow was within normal limit (Table 3).
Table 3
Spx lO-day group
+
CP
Spx 20-day group
+
CP
Erythrocyte (X 104/cmm) 866±75t** 878±74**
1 h
6 h
24 h
48 h
1 h
6 h
24 h
48 h
Liver
Bone
Marrow
C
<U
U
...
<U
~
Reticulocyte (%0) 26± 5 I 29± 7
I
Plasma Fe (?'/dl) 320 403
P.I.D.T. (min.) 75±10 80±15
59Fe Reappearance I 24 h 58±10 61±13
rate (%) 48 h 74± 6 74±13
""-
9.2±3.1 8.8±1.1
13.1±2.2 9.5±2.5
13.1 ±2.2 13.7±1.5
12.4±1.1 15.0±1.6
26.0±6.5 23.4±3.9
23.1 ±9.1* 32.4±3.9
23.4±9.1 I 16.9±2.6
I1O.4±1.3
I
9.1±1.3
---------_._--~-~---.-----
t : Mean value±standard deviation.
* : P value showed significant difference less than 1 per cent error (p <0.01),
** : less than 5 percent (p <0.05) comparing normal gro\.lp.
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8. H. G. G. group: This group showed elevated plasma iron levels,
prolonged P. 1. D. T. and decreased 69Fe reappearance rate. These results
were analogous to those of CP 3-day group but conversely the uptake of
bone marrow was significantly decreased (Table 4).
9. H. G. G. & F. C. Adj. group: This group showed markedly high
plasma iron level, prolonged P.1. D. T. and decreased 69Fe uptake of the
bone marrow (Table 4).
10. Chlorabulin group: There were little changes in the ferrokinetics
study except elevated plasma iron levels (Table 4).
Table 4
H. G. G. group H.G.G. &F. C. Adj. group
Chlorabulin
group
Erythrocyte (X l04/cmm) 1231 ±189t 979± 144 931 ±146
Reticulocyte (%0) 21±3 38±29 29±8
---
Plasma Fe (?'jdl) 356 465 306
P. I. D. T. (min.) 9O±15** 80±20 9O±25
59Fe Reappearance
I
24 h 68±12 79±11 66±16
rate (%) 48 h 77±12 89± 7 72±24
I h 7.0±0.6 7.5±0. 7 8.8±2.0
6 h 13.9±0.8 9.8±1.8* 11.9±0.3
~ Liver 12.4±1.2 9.7±2.224 h 12.8±1.1
\) 48 h 12.3±2.7 8.8±1.7 12.1±1.2
....:
til
0.. I h 5.4±1.5 1O.6±2.3 3.2±1.6
;:l 6 h 1O.2±1.5 1O.4±2.2 9.5±3.8
c Spleentil 24 h 5.9±1.2 8.5±1.7** 1.9±0.3Of)
...
0 48 h 1.8±0.3 6.S±2.6 1.7±O.2*
-=
I
\) I h 24.7±3.9 II. 7± 1.3* IS.6±3.9u
...
\) Bone 6 h 20.8±3.9* 18.2±5.2* 29.9±9.1~
Marrow 24 h 16.9±S.2 14.3±S.2 13.0±2.6
48 h 9.1±1.3 6.5±0 7.8±0
t : Mean value±standa~d deviation.
* . P value ShONd significant difference less than I percent error (p <0.01),
** : less than S percent (p < O.OS) comparing normal group.
DISCUSSION
The ferrokinetics study using 6vFe is useful to solve the problems of
erythropoiesis not only in human hematological disorders but also In
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experimental animals. Few informations of normal mouse erythrokinetics
using li9Fe are available with regard to comparative physiology, erythro.
poietic stimulating factor assays and a proper evaluation of abnormal
erythropoiesis (6, 7, 8). The uptake into and release of li9Fe from the spleen
paralleled the li9Fe P. I. D. T. and li9Fe reappearance rate in the peripheral
erythrocytes of normal mice. Active erythropoiesis was demonstrated in
the histology and liliFe radio.autography of the spleen of normal mice.
Reversible bone marrow depression due to chloramphenicol (CP) was
first observed by KRAKOFF, KARNOFSKY and BURCHENAL (9) during the admi.
nistration of large doses (6 to 12 gm per day) of the drug. RUBIN and his
coworkers (10) showed that in some patients conventional doses of chloram-
phenicol produced changes in iron metabolism that could precede other
evidences of erythropoietic depression, whereas SAIDI, WALLERSTEIN and
AGGELER (11) found that this effect of the drug was often accompanied
by toxic vacuolation of the bone marrow erythroblasts, particularly when
larger doses were employed or when accelerated erythropoiesis or infection
were present, A number of cases of hypoplastic anemia associated with
chloramphenicol therapy have been recorded in the literature (12, 13, 14,
15, 16, 17). The nature of the toxic effects of chloramphenicol on the bone
marrow has been studied (10, 11, 18, 19). YUNIS (18) described two types of
bone marrow reaction to chloramphenicol. The first is a reversible effect
that is predictable, dose. dependent, not characterized by hypoplasia and
has been produced experimentally. The second type is a later, idiosyncratic
response regularly associated with hypoplasia. This usually irreversible
aplastic response to chloramphenicol, as described by YUNIS, occurred
later after the inception of chloramphenicol therapy and followed a larger
dosage given over a longer period. Although chloramphenicol continues
to be a leading cause of drug-induced hypoplastic anemia, little progress
has been made in elucidating the mechanism of its toxic effect. In chloram.
phenico1 sensitive bacteria chloramphenicol in low concentrations causes
complete inhibition of protein synthesis. There is good evidence that this
action is exacted through stereospecific binding of the drug to the 50S
ribosomal subunit, thereby inhibiting the formation of the peptide bond.
The drug does not seem to interfere with the function of messenger RNA
(mRNA) (20). Recently, WEISBERGER et at. (21) reported profoundin hibi-
tion of mRNA-induced protein synthesis in a ('ell. free system from rabbit
reticulocytes by a low concentration of chloramphenicol, reversed by
increasing the concentration of messenger. They concluded that chloram.
phenico1 inhibits protein synthesis in mammalian cells by interfering with
the binding of mRNA to ribosomes. Whether hematologic toxicity of
6
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chloramphenicol is related to its inhibitory effect on protein synthesis
cannot be resolved at present. Several observations in patients with chlo-
ramphenicol-induced hypoplastic anemia suggest that this drug exerts its
action at the stem-cell level. BRAUER and DAMESHEK (22) suggested a
possibility that acute leukemia would be seen much more frequently in
patients with chloramphenicol-induced bone marrow aplasia if they sur-
vived longer. However, little can be said about this suggestion until the
basic mechanisms by which chloramphenicol and other drugs injure the
bone marrow are clarified.
Concerning CP toxicity on the hematopoietic organ in the experimental
animal, only one paper has been recently published by SUGA et al. in
Japan (23). This paper elucidated that the suppression of hematopoiesis
by CP was independent of the erythropoietic activity but dependent upon
the dose of administered CPo
The data presented in this paper indicated that elevated plasma iron
levels, prolonged P. I. D. T., and decreased 59Fe reappearance rate were
demonstrated following 3-day or 30.day administration of CPo The uptake
of the spleen was suppressed in 3-day group and that of the bone marrow
was suppressed in 3D-day group. Therefore, short-term administration of
CP suppressed the erythropoietic function in the spleen and long-term
administration of CP suppressed it in the bone marrow. Consequently,
the pathogenesis of CP induced anemia is presumed to be the direct
damage of the hematopoietic organs by CP administration. As mentioned
previously, CP administration augu~ented the RES function of spleen
and liver, and this hyperfunction of RES in these organs will suppress still
further the hematopoiesis in the bone marrows.
As already mentioned in the preface, conclusive evidence concerning
the spleen and hematopoiesis is not yet available. Ferrokinetic studies were
also carried in splenectomized mice to investigate the relatioship of the
spleen to the hematopoiesis. Ten days after spleneotomy, erythrocyte
counts were decreased but the uptake of 59Fe in the bone marrow was
elevated. Twenty days after splenectomy, erythrocyte counts recovered to
normal and 59Fe uptake in the bone marrow was increased. These data
indicated that splenectomy induced hyper-erythropoiesis in the bone mar·
row. By CP administration in splenectomized mice the plasma iron level
was elevated and the uptake of the bone marrow was suppressed. There-
fore, CP administration suppressed the accentuated hematopiesis in the
bone marrow which was induced by splenectomy.
The clinical use of gammaglobulin administration poses many prob-
lems, and little is known about the mechanism of its pharmacological
7
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effects. The author's experiments indicated that hematopoiesis in the bone
marrow was suppressed by gammaglobulin administration. But concerning
RES function, the bone marrow was accentuated but the spleen and liver
were suppressed. Hypersensitization with gammaglobulin and Freund's
complete adjuvant made the hematopoiesis in the bone marrow suppressed.
Therefore, hyperfunction of the RES in the spleen will suppress the
hematopoiesis in the bone marrow. The Chlorabulin administration was
followed by suppressed erythropoiesis.
CONCLUSION
The following conclusions were drawn from the ferrokinetic studies
using 69Fe in mice, whose hematological disorders were induced by various
treatments.
1. The ferrokinetics in the normal mice were studied.
2. Chloramphenicol (CP) administration in mice first induced ferro-
kinetics disturbances and then suppressed erythropoiesis.
3. Splenectomy induced hyper-erythropoiesis in the bone marrow,
and CP administration after splenectomy suppressed this hyper-erythro-
poiesis.
4. Human gamma-globulin (H. G. G.) caused hypersplenism and a
marked suppression of erythropoiesis in the bone marrow, and Chlorabulin
administration suppresed erythropoiesis.
Finally, the author has summarized the relationship of the RES
function and hematopoiesis in mice as follows.
1. The spleen and liver reacted in the same manner with respect to
the RES function to sequestrate blCr-labelled heat-damaged erythrocytes
when hematological failures were induced.
2. The spleen and bone marrow reacted reversely with regard to the
RES function.
3. When the RES function, especially that of the spleen was accen-
tuated, the suppression of hematopoiesis was observed.
4. Chloramphenicol administration was followed by the suppressed
hematopoiesis and the accentuated RES function.
5. Splenectomy accentuated the RES function in the bone marrow
and liver, and also increased hematopoiesis in the bone marrow.
6. Human r-globulin hypersensitization induced hyperfunction of the
RES, especially of the spleen and suppression of the hematopoiesis.
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